

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Christopher J. R. Paszty, et al.

Serial No.: Not assigned yet

Group Art Unit No.: Not known yet

Filed: Concurrently herewith

Examiner: Not known yet

For: BETA-LIKE GLYCOPROTEIN HORMONE
POLYPEPTIDE AND HETERODIMER

Docket No.: A-676A

**INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner. The relevance of each listed reference is discussed in the following paragraphs.

Citation B1

Relates to polynucleotide and polypeptide molecules for "zsig51", which is described as a novel member of the cystine knot family. The patent publication on its face claims priority from a United States application filed on February 13, 1998, which is prior to the filing date of the present application.

Citation C1

Review article which describes the importance of the influence of glycosylation on the biology of FAS, TSH and the gonadotropins (FSH, LH, CG).

Citation C2

Describes the basic biology of TSH, its normal physiological function, and the various clinical disorders associated with TSH.

Citation C3

Describes the basic biology (amino acids, glycosylation, functions) of the heterodimeric gonadotropins (FSH, LH and CG).

EXPRESS MAIL CERTIFICATE"Express Mail" mail labeling number: EL198798721USDate of Deposit: November 27, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum
Printed NameLynne Buchsbaum
Signature

Citation C4

Describes the genomic structure of the CG gene cluster in humans and demonstrates that there are six genes in humans and that these genes are probably all transcribed.

Citation C5

Describes one of the functions of the glycoprotein hormone free alpha subunit (FAS), which is the differentiation of prolactin-producing cells (lactotrophs) in pituitary tissue.

Citation C6

Describes one of the functions of the glycoprotein hormone free alpha subunit, which is the differentiation of human decidual cells (prolactin-producing cells) from endometrial stromal cells.

Citation C7

Describes one of the functions of the glycoprotein hormone free alpha subunit, which is the stimulation of prolactin secretion from placental decidual cells.

Citation C8

Describes the roles of heterodimeric gonadotropins (FSH, LH and CG) in normal physiology and also in clinical disorders associated with these hormones.

Citation C9

Describes current clinical trial uses of TSH.

Citation C10

Describes current clinical trial uses of CG and the menotropins (FSH and LH).

Citation C11

Describes the three dimensional structures of human glycoprotein hormone alpha polypeptide, CG-beta polypeptide and CG heterodimer. Based on these structures, the glycoprotein hormone family was placed in the cystine knot growth factor structural superfamily.

Citation C12

Describes the critical structural motifs of the growth factor cystine knots, as well as the gene families that comprise the cystine knot growth factor structural superfamily.

Citation C13


Describes one of the functions of glycoprotein hormone free alpha subunit (FAS), which is the stimulation of prolactin-producing cells (lactotrophs) in pituitary tissue.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Richard J. Mazza
Attorney for Applicants
Registration No.: 27,657
Phone: (805) 447-4112
Date: November 27, 2000

Please send all future correspondence to:

US Patent Operations/RJM
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799